Furthermore, nuclear expression of bothHIF-1α and HIF-2α has been observed in the majority ofpatient samples examined in a wide range of solid tumors, includingbreast, colon, ovarian, and pancreatic, indicating that both isoforms(HIF-1 and HIF-2) are driving hypoxia response in these tumors.45 Thus, the therapeutic strategy of inhibitingboth HIF-1 and HIF-2 can be reasonably envisaged to be superior tothe inhibition of just a single HIF isoform for most cancers. The gene discussed is HIF1A; the disease is cancer.